Optimi Health Corp.
corporate_fare Company Profile
Optimi Health Corp. (NASDAQ:OPTH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for OPTH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-23, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for OPTH spans 6-K, 424B3.
Recent high-impact activity:
- Optimi Health Completes Production Batch Supplying Phase 2 MDD Trial and Australian Commercial Supply
- Optimi Completes Psilocybin Batch for Phase 2 MDD Trial and Australian Supply
- Optimi Health Secures Health Canada Nod for Phase 3 MDMA PTSD Trial
- Optimi Health to Launch Phase 3 MDMA Trial for PTSD in 2027
- Optimi Health to Launch 200-Patient Phase 2 Psilocybin Trial for Major Depressive Disorder
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 20,500 shares in OPTH as of the September 15, 2026 settlement, a 109.1% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 14.3% of OPTH volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for OPTH, detected from its recent SEC filings · based on capital-structure filings through 2026-08-27.
21.9M Shares Registered for Resale · VWAP-Based Purchase Mechanics
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
OPTH files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.